Effects of Antioxidants on Human Macular Pigments
Nyckelord
Abstrakt
Datum
| Senast verifierad: | 01/31/2009 |
| Först skickat: | 07/16/2008 |
| Beräknad anmälan inlämnad: | 07/16/2008 |
| Först publicerad: | 07/20/2008 |
| Senaste uppdatering skickad: | 02/26/2009 |
| Senaste uppdatering publicerad: | 03/02/2009 |
| Faktiskt startdatum för studien: | 08/31/2004 |
| Uppskattat primärt slutdatum: | 11/30/2007 |
| Beräknat slutfört datum: | 11/30/2007 |
Tillstånd eller sjukdom
Intervention / behandling
Dietary Supplement: 1
Dietary Supplement: 2
Fas
Armgrupper
| Ärm | Intervention / behandling |
|---|---|
| Experimental: 1 lutein | Dietary Supplement: 1 Lutein (12 mg/d) |
| Experimental: 2 Lutein plus green tea extract | Dietary Supplement: 2 lutein (12 mg/d) plus green tea extract (200 mg/d) |
Urvalskriterier
| Åldrar berättigade till studier | 50 Years Till 50 Years |
| Kön som är berättigade till studier | All |
| Accepterar friska volontärer | Ja |
| Kriterier | Inclusion Criteria: - Normal hematologic parameters, normal serum albumin, normal liver function, normal kidney function, absence of fat malabsorption and no drug intake which would interfere with fat absorption, metabolism or blood clotting - non-smokers Exclusion Criteria: - A history of kidney stones, active small bowel disease or resection, atrophic gastritis, hyperlipidemia, insulin-requiring diabetes, alcoholism, pancreatic disease, or bleeding disorders - Exogenous hormone users - weighing greater than 20% above or below the NHANES median standard - subjects with serum lutein/zeaxanthin concentrations that are more than 150 % of median of normal population (as previously reported in NHANES III at same age group) - early age related macular degeneration, cataract, or glaucoma except for those with age appropriate progression of the eye status. |
Resultat
Primära resultatåtgärder
1. macular pigments, Plasma lutein concentrations [Every month - baseline, 1, 2, 3, & 4 months]
